PDC*LINE PHARMA
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Franรงais du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.
PDC*LINE PHARMA
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-04-01
Address:
La Tronche, Rhone-Alpes, France
Country:
France
Website Url:
http://www.pdc-line-pharma.com
Total Employee:
1+
Status:
Active
Contact:
+33 (0) 4 84 35 05 04
Email Addresses:
[email protected]
Total Funding:
41.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics Font Awesome Euro Google Maps
Similar Organizations
![]()
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Elstar Therapeutics
Fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
![]()
![]()
![]()
Founder
![]()
Investors List
Hansongneotech
Hansongneotech investment in Series B - PDC*line Pharma
Alpha Holdings
Alpha Holdings investment in Series B - PDC*line Pharma
S.R.I.W.
S.R.I.W. investment in Series B - PDC*line Pharma
![]()
Korea Investment Partners
Korea Investment Partners investment in Series B - PDC*line Pharma
![]()
UTC Investment Co.
UTC Investment Co. investment in Series B - PDC*line Pharma
Brain Asset Management
Brain Asset Management investment in Series B - PDC*line Pharma
![]()
SFPI-FPIM
SFPI-FPIM investment in Series B - PDC*line Pharma
![]()
Sambrinvest
Sambrinvest investment in Series B - PDC*line Pharma
![]()
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series B - PDC*line Pharma

Shinhan-Cognitive Start-up Fund
Shinhan-Cognitive Start-up Fund investment in Series B - PDC*line Pharma
Official Site Inspections
http://www.pdc-line-pharma.com Semrush global rank: 9.33 M Semrush visits lastest month: 174
- Host name: cluster013.ovh.net
- IP address: 213.186.33.24
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
